In an e-mailed response, GSK's Rawcliffe states that the company knew SIRT1 modulation in vitro ... might yield health benefits through other pathways. Thomas Hughes, president and CEO of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback